Fulcrum Therapeutics, a Cambridge, Mass.-based company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, raised $80m in Series B financing.
The round was led by Foresite Capital, with participation from Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors. In conjunction with the funding, Jim Tananbaum, M.D., of Foresite Capital will join the Board of Directors at Fulcrum.
The company intends to use the funds to advance its lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically-based neuromuscular, central nervous system and hematologic disorders.
Led by Robert J. Gould, Ph.D., President and Chief Executive Officer, Fulcrum is advancing a small molecule, precision medicine approach to address serious monogenic and prevalent diseases of gene misregulation. By focusing on disease-causative genes, the company is unlocking druggable mechanisms that regulate disease to develop a new generation of therapies in various therapeutic areas.
In partnership with the FSHD Clinical Trial Research Network (CTRN), Fulcrum has initiated clinical trial readiness studies in FSHD.